Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 85% based on the firm’s underlying fundamentals and the stock’s valuation.

Pfizer Inc (PFE) stock saw a decline, ending the day at $26.3 which represents a decrease of $-0.19 or -0.72% from the prior close of $26.49. The stock opened at $26.4 and touched a low of $26.22 ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable ...

Ritholtz Wealth Management decreased its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 39.4% during the 4th ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

Shares of Pfizer Inc. PFE advanced 1.03% to $26.49 Thursday, on what proved to be an all-around rough trading session for the ...

Pfizer (PFE) is one of the stocks most watched by ... stream of earnings is what determines the fair value for its stock. Our analysis is essentially based on how sell-side analysts covering ...

For cautious investors, this could be a signal to steer clear of Pfizer Inc (NYSE:PFE), a stock with a history of underperforming in January. According to data from Schaeffer's Senior Quantitative ...

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price fell 0.8% during trading on Thursday after UBS Group lowered their price target on the stock from $31.00 to $29.00. UBS Group currently has a ...